Modeling To Inform Payer Communications and Policy – Optimizing Treatment Sequences in Multiple Immunology Indications
Health systems view low-cost therapeutic alternatives (biosimilars and generics) as opportunities to reduce their medicine spend. However, this approach focuses on costs only and not outcomes, which results in the adoption of ‘low-cost first’ blanket policies regardless of biologic class or therapy area. Consequently, patients are left to cycle through low-cost options before they can access the most effective treatments
Case Study Feb 18, 2022